| # | Title | Journal | Year | Citations |
|---|
| 1 | Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study | Lancet Haematology,the | 2020 | 430 |
| 2 | The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience | American Journal of Hematology | 2011 | 47 |
| 3 | Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release | Cell Reports | 2016 | 32 |
| 4 | A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study | Blood Advances | 2022 | 28 |
| 5 | Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors | Blood | 2019 | 13 |
| 6 | Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia | Blood | 2017 | 12 |
| 7 | Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients | Frontiers in Oncology | 2020 | 11 |
| 8 | Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden | Cancers | 2021 | 10 |
| 9 | Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study | British Journal of Haematology | 2022 | 10 |
| 10 | Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report | Hematological Oncology | 2021 | 9 |
| 11 | Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients | European Journal of Haematology | 2006 | 7 |
| 12 | JAK Inhibition with Ruxolitinib in Patients with COVID-19 and Severe Pneumonia: Multicenter Clinical Experience from a Compassionate Use Program in Italy | Journal of Clinical Medicine | 2021 | 7 |
| 13 | Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase 2 Superiority Trial | Blood | 2019 | 7 |
| 14 | Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) | Frontiers in Oncology | 2022 | 6 |
| 15 | Treatment decisions and outcome in very elderly patients with diffuse large B‐Cell lymphoma | Cancer | 2015 | 4 |
| 16 | First reported case of secondary mixed phenotype acute leukemia after multiple myeloma | American Journal of Blood Research | 2021 | 4 |
| 17 | Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) | Oncologist | 2018 | 3 |
| 18 | Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial | Blood | 2019 | 3 |
| 19 | P698: BOSUTINIB DOSE OPTIMIZATION IN THE SECOND-LINE TREATMENT OF ELDERLY CML PATIENTS: EXTENDED 3-YEAR FOLLOW-UP AND FINAL RESULTS OF THE BEST STUDY | HemaSphere | 0 | 3 |
| 20 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation | Journal of Clinical Medicine | 2020 | 2 |
| 21 | Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study | Medicina (Lithuania) | 2021 | 2 |
| 22 | Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation | Blood | 2019 | 2 |
| 23 | Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy | Blood | 2016 | 2 |
| 24 | Assessing gene function in human B cells: CRISPR/Cas9‐based gene editing and mRNA‐based gene expression in healthy and tumor cells | European Journal of Immunology | 2022 | 2 |
| 25 | Blinatumomab and Inotuzumab for the Treatment of Multiply Relapsed Acute Lymphoblastic Leukemia: A Real-Life Campus ALL Study | Blood | 2021 | 1 |
| 26 | Pro-Inflammatory and Pro-Oxidative Changes during Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) | Blood | 2021 | 1 |
| 27 | Editorial: Molecular Mechanisms of Multiple Myeloma | Frontiers in Oncology | 2022 | 1 |
| 28 | A multicentre phase II trial addressing lenalidomide (LEN) maintenance in patients with relapsed diffuse large b-cell lymphoma (rDLBCL) who are not eligible for autologous stem cell transplantation (ASCT) | Annals of Oncology | 2017 | 0 |
| 29 | Addition of the Anti-CD33 Monoclonal Antibody Mylotarg to Fludarabine/High Dose Cytarabine - Based Induction Significantly Improves Outcome in Patient Affected By FLT3-ITD Positive Cytogenetically Normal Acute Myeloid Leukemia | Blood | 2019 | 0 |
| 30 | A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation | Blood | 2019 | 0 |
| 31 | Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden | Blood | 2019 | 0 |
| 32 | ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report | Blood | 2021 | 0 |
| 33 | Nutrition As a Predictor of Microbiome Injury in Allo-HCT | Blood | 2021 | 0 |
| 34 | P1098: OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY. | HemaSphere | 0 | 0 |
